Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (SKYE) ("Skye"), a ...
Skye Bioscience, Inc., a biotechnology company specializing in treatments for obesity and metabolic disorders, announced the launch of its "Anatomy of Progress" video series, showcasing the ...
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and ...
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs targeting the endocannabinoid system, announced today that it plans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results